JP2010518810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518810A5 JP2010518810A5 JP2009547686A JP2009547686A JP2010518810A5 JP 2010518810 A5 JP2010518810 A5 JP 2010518810A5 JP 2009547686 A JP2009547686 A JP 2009547686A JP 2009547686 A JP2009547686 A JP 2009547686A JP 2010518810 A5 JP2010518810 A5 JP 2010518810A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- disease
- substance
- treg cells
- treg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003289 regulatory T cell Anatomy 0.000 claims description 47
- 239000000126 substance Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 17
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 13
- 239000012190 activator Substances 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 230000003993 interaction Effects 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 6
- 230000001363 autoimmune Effects 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 238000002054 transplantation Methods 0.000 claims 4
- 201000011152 Pemphigus Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 206010001889 Alveolitis Diseases 0.000 claims 2
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 2
- 206010016946 Food allergy Diseases 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 2
- 208000036495 Gastritis atrophic Diseases 0.000 claims 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 201000009053 Neurodermatitis Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000010265 Sweet syndrome Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000009961 allergic asthma Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000028004 allergic respiratory disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 2
- 235000020932 food allergy Nutrition 0.000 claims 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 201000002364 leukopenia Diseases 0.000 claims 2
- 231100001022 leukopenia Toxicity 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 201000004335 respiratory allergy Diseases 0.000 claims 2
- 201000003068 rheumatic fever Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 206010043778 thyroiditis Diseases 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 206010039580 Scar Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07101604 | 2007-02-01 | ||
| EP07101604.2 | 2007-02-01 | ||
| EP07122424.0 | 2007-12-05 | ||
| EP07122424 | 2007-12-05 | ||
| PCT/EP2008/051144 WO2008092905A2 (en) | 2007-02-01 | 2008-01-30 | Specific activation of a regulatory t cell and its use for treatment of asthma, allergic disease, autoimmune disease, graft rejection and for tolerance induction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014097086A Division JP6038070B2 (ja) | 2007-02-01 | 2014-05-08 | 調節性ｔ細胞の特異的活性化ならびに喘息、アレルギー疾患、自己免疫疾患、移植片拒絶の治療および免疫寛容の誘導のためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010518810A JP2010518810A (ja) | 2010-06-03 |
| JP2010518810A5 true JP2010518810A5 (https=) | 2013-10-24 |
| JP5867795B2 JP5867795B2 (ja) | 2016-02-24 |
Family
ID=39363828
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009547686A Expired - Fee Related JP5867795B2 (ja) | 2007-02-01 | 2008-01-30 | 調節性ｔ細胞の特異的活性化ならびに喘息、アレルギー疾患、自己免疫疾患、移植片拒絶の治療および免疫寛容の誘導のためのその使用 |
| JP2014097086A Active JP6038070B2 (ja) | 2007-02-01 | 2014-05-08 | 調節性ｔ細胞の特異的活性化ならびに喘息、アレルギー疾患、自己免疫疾患、移植片拒絶の治療および免疫寛容の誘導のためのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014097086A Active JP6038070B2 (ja) | 2007-02-01 | 2014-05-08 | 調節性ｔ細胞の特異的活性化ならびに喘息、アレルギー疾患、自己免疫疾患、移植片拒絶の治療および免疫寛容の誘導のためのその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US8557533B2 (https=) |
| EP (2) | EP3112866B1 (https=) |
| JP (2) | JP5867795B2 (https=) |
| CA (1) | CA2676170C (https=) |
| ES (2) | ES2825718T3 (https=) |
| WO (1) | WO2008092905A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007127787A2 (en) | 2006-04-25 | 2007-11-08 | Joslin Diabetes Center, Inc. | Insulin autoantigen-specific regulatory cd4+ t cells |
| WO2008092905A2 (en) * | 2007-02-01 | 2008-08-07 | Boehringer Ingelheim International Gmbh | Specific activation of a regulatory t cell and its use for treatment of asthma, allergic disease, autoimmune disease, graft rejection and for tolerance induction |
| EP2260057B1 (en) | 2008-03-13 | 2016-11-23 | Biotest AG | Anti-CD4 antibody dosage regimen for treating autoimmune disease |
| EP2265643B1 (en) | 2008-03-13 | 2016-10-19 | Biotest AG | Dosing regimen for treating psoriasis and rheumatoid arthritis |
| RU2540013C2 (ru) | 2008-03-13 | 2015-01-27 | Биотест Аг | Средство для лечения заболевания |
| DK2318020T3 (en) * | 2008-06-30 | 2015-11-30 | Universitätsklinikum Heidelberg | Immunosuppressive blood cells and methods of producing same |
| GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
| EP2471543A1 (en) * | 2010-12-02 | 2012-07-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules |
| EP2691515A2 (en) * | 2011-03-31 | 2014-02-05 | President and Fellows of Harvard College | A unique population of regulatory t cells that regulate tissue regeneration and wound healing |
| US20160271086A1 (en) * | 2013-10-31 | 2016-09-22 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for inducing regulatory t-cell generation |
| WO2019099788A1 (en) * | 2017-11-16 | 2019-05-23 | Benaroya Sesearch Institute At Virginia Mason | Antigen-specific t regulatory cell assay |
| GB202401501D0 (en) | 2024-02-05 | 2024-03-20 | T Balance Therapeutics Gmbh | Medical use of regulatory t cell activator |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4695459A (en) * | 1984-12-26 | 1987-09-22 | The Board Of Trustees Of Leland Stanford Junior University | Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells |
| IE872748L (en) * | 1986-10-16 | 1988-04-16 | Arjomari Europ | Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells |
| JPH0768273B2 (ja) * | 1988-12-02 | 1995-07-26 | カルピス食品工業株式会社 | 抗ｈｉｖペプチド |
| AU6523590A (en) * | 1989-09-22 | 1991-04-18 | Idec Pharmaceuticals Corporation | Novel peptides associated with the cd4 binding region of gp120 and their methods of use |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0789076A3 (en) | 1996-02-07 | 1999-04-14 | Takeda Chemical Industries, Ltd. | G protein coupled receptor proteins, their production and use |
| US6585979B1 (en) * | 1996-07-08 | 2003-07-01 | Genentech, Inc. | HIV envelope polypeptides and immunogenic composition |
| EP1066047A4 (en) * | 1998-03-25 | 2004-10-13 | Mayo Foundation For Medicaledu | METHOD AND SUBSTANCES FOR TREATING FLAMMABLE DISEASES |
| US7608273B2 (en) * | 1998-08-12 | 2009-10-27 | University Of Western Ontario | Recombinant lentivirus encoding modified GP 120 signal sequences |
| US6337181B1 (en) * | 1998-12-21 | 2002-01-08 | Jeffrey Joseph Stewart | Method of specifying vaccine components for viral quasispecies |
| AU2487300A (en) * | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| SE9904660D0 (sv) | 1999-12-17 | 1999-12-17 | Astra Pharma Inc | Novel assays |
| EP1241249A1 (en) | 2001-03-12 | 2002-09-18 | Gerold Schuler | CD4+CD25+regulatory T cells from human blood |
| WO2003065044A2 (en) | 2002-02-01 | 2003-08-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with gpr72 |
| WO2004072296A2 (en) * | 2003-01-30 | 2004-08-26 | The General Hospital Corporation | Compositions for modulating immune cell activity and methods for detection thereof |
| EP1460088A1 (en) * | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
| US20050048587A1 (en) * | 2003-07-17 | 2005-03-03 | Tolerrx, Inc. | Methods for identifying tolerance modulatory compounds and uses therefor |
| WO2006085959A2 (en) * | 2004-06-08 | 2006-08-17 | Novartis Vaccines And Diagnostics Inc. | Fusion proteins comprising cd4 minimal modules and methods of use thereof |
| JP2009509142A (ja) * | 2005-09-19 | 2009-03-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 調節性Ｔ細胞機能をモジュレート（ｍｏｄｕｌａｔｅ）し得るＧＰＲ８３アゴニストおよびＧＰＲ８３アンタゴニストを同定するための方法 |
| WO2008092905A2 (en) | 2007-02-01 | 2008-08-07 | Boehringer Ingelheim International Gmbh | Specific activation of a regulatory t cell and its use for treatment of asthma, allergic disease, autoimmune disease, graft rejection and for tolerance induction |
-
2008
- 2008-01-30 WO PCT/EP2008/051144 patent/WO2008092905A2/en not_active Ceased
- 2008-01-30 EP EP16166807.4A patent/EP3112866B1/en active Active
- 2008-01-30 ES ES16166807T patent/ES2825718T3/es active Active
- 2008-01-30 JP JP2009547686A patent/JP5867795B2/ja not_active Expired - Fee Related
- 2008-01-30 US US12/525,142 patent/US8557533B2/en not_active Expired - Fee Related
- 2008-01-30 CA CA2676170A patent/CA2676170C/en active Active
- 2008-01-30 ES ES08708459.6T patent/ES2593789T3/es active Active
- 2008-01-30 EP EP08708459.6A patent/EP2109770B1/en not_active Not-in-force
-
2013
- 2013-09-19 US US14/031,919 patent/US20140093509A1/en not_active Abandoned
-
2014
- 2014-05-08 JP JP2014097086A patent/JP6038070B2/ja active Active
-
2016
- 2016-10-05 US US15/285,561 patent/US10729742B2/en active Active
-
2020
- 2020-06-25 US US16/912,199 patent/US20200316167A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518810A5 (https=) | ||
| US11708392B2 (en) | Peptide conjugates | |
| Park et al. | The role of T cells in obesity-associated inflammation and metabolic disease | |
| ES2709176T3 (es) | Péptidos inmunogénicos y su uso en trastornos inmunitarios | |
| CN104470943B (zh) | 新肽及其用途 | |
| JP6108660B2 (ja) | 細胞透過性ペプチドを用いたキナーゼ阻害剤 | |
| AU2012257774B2 (en) | High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain | |
| CN108431023B (zh) | 治疗黑皮质素-4受体途径相关病症的方法 | |
| TW200835513A (en) | HLA-A* 1101-restricted WT1 peptide and pharmaceutical composition comprising the same | |
| HUE027237T2 (en) | Compositions and methods for treatment of celiac disease | |
| JP2011528332A (ja) | 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置 | |
| CN110381976A (zh) | 包括肽wkdeagkplvk的组合物 | |
| JP6898225B2 (ja) | Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 | |
| KR20130128404A (ko) | 면역 관용 유도 및 면역진단을 위한 ｆｖｉｉｉ 펩타이드 | |
| CN112409450B (zh) | TIGIT-IgV的亲和剂及其应用 | |
| ES2763315T3 (es) | Antagonistas del canal de potasio KV1.3 | |
| US20240043475A1 (en) | Peptide conjugates | |
| Shkair et al. | Immunogenic properties of MVs containing structural hantaviral proteins: an original study | |
| CN109311959A (zh) | 肽类似物 | |
| EP3356389A1 (en) | Use of human derived immunosuppressive proteins and peptides as medicaments | |
| EP2983706A2 (en) | Use of immune suppressive domains as medicaments | |
| JP2012532621A (ja) | 治療ペプチド、ポリペプチド及び核酸配列 | |
| JP5580047B2 (ja) | ＤｎａＫの精製方法 | |
| CN103304646B (zh) | 结核分枝杆菌候选抗原多肽及其应用 | |
| US20130225508A1 (en) | Peptide capable of binding to immunoglobulin |